Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results

Gene therapy for sickle cell disease is limited by the yield of hematopoietic progenitor cells that can be harvested for transduction or gene editing. We therefore performed a phase I dose-escalation study of the hematopoietic progenitor cell mobilizing agent plerixafor to evaluate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulad, Farid, Shore, Tsiporah, van Besien, Koen, Minniti, Caterina, Barbu-Stevanovic, Mihaela, Fedus, Sylvie Wiener, Perna, Fabiana, Greenberg, June, Guarneri, Danielle, Nandi, Vijay, Mauguen, Audrey, Yazdanbakhsh, Karina, Sadelain, Michel, Shi, Patricia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927989/
https://www.ncbi.nlm.nih.gov/pubmed/29419425
http://dx.doi.org/10.3324/haematol.2017.187047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927989/
https://www.ncbi.nlm.nih.gov/pubmed/29419425
http://dx.doi.org/10.3324/haematol.2017.187047

Ejemplares similares